Insider Selling: Loxo Oncology Inc (LOXO) CEO Sells 15,000 Shares of Stock

Loxo Oncology Inc (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 15,000 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $96.57, for a total transaction of $1,448,550.00. Following the transaction, the chief executive officer now owns 190,207 shares in the company, valued at approximately $18,368,289.99. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Loxo Oncology Inc (LOXO) traded up $3.43 on Thursday, reaching $104.35. 504,000 shares of the company traded hands, compared to its average volume of 335,555. The company has a market cap of $3,120.00, a P/E ratio of -17.96 and a beta of 2.56. Loxo Oncology Inc has a 12-month low of $40.01 and a 12-month high of $108.50.

A number of research analysts have recently weighed in on LOXO shares. Citigroup cut their price target on shares of Loxo Oncology from $112.00 to $108.00 and set a “buy” rating on the stock in a report on Thursday, November 16th. BidaskClub upgraded shares of Loxo Oncology from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Zacks Investment Research upgraded shares of Loxo Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. William Blair started coverage on shares of Loxo Oncology in a report on Tuesday, November 28th. They set an “outperform” rating on the stock. Finally, JMP Securities upgraded shares of Loxo Oncology from a “market perform” rating to an “outperform” rating and raised their price target for the company from $77.18 to $95.00 in a report on Tuesday, November 14th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Loxo Oncology has a consensus rating of “Buy” and an average target price of $97.33.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Great West Life Assurance Co. Can raised its holdings in Loxo Oncology by 195.8% in the 3rd quarter. Great West Life Assurance Co. Can now owns 2,958 shares of the biopharmaceutical company’s stock worth $275,000 after acquiring an additional 1,958 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Loxo Oncology by 38.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,597 shares of the biopharmaceutical company’s stock worth $1,251,000 after acquiring an additional 4,357 shares during the period. Parametrica Management Ltd acquired a new stake in Loxo Oncology in the 3rd quarter worth $500,000. Cornerstone Capital Management Holdings LLC. acquired a new stake in Loxo Oncology in the 3rd quarter worth $847,000. Finally, Vanguard Group Inc. grew its position in Loxo Oncology by 24.7% in the 2nd quarter. Vanguard Group Inc. now owns 914,719 shares of the biopharmaceutical company’s stock worth $73,351,000 after purchasing an additional 181,471 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Loxo Oncology Inc (LOXO) CEO Sells 15,000 Shares of Stock” was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.themarketsdaily.com/2018/02/15/insider-selling-loxo-oncology-inc-loxo-ceo-sells-15000-shares-of-stock.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply